MyMeds&Me will be attending DIA's Pharmacovigilance and Risk Management Strategies Conference in Washington DC, 29-30 January 2019. The three-day conference will focus on new developments and the future direction for regulations and guidance on safety, pharmacovigilance, and risk management strategies.
International regulators - including those from the US and the EU – and wider industry experts will discuss evolving global regulatory requirements and challenged faced across the landscape, and MyMeds&Me will be in attendance with other leaders from the biopharmaceutical and pharmacovigilance industries to gain and contribute fresh insight into the latest developments.
Andy Watson, Chief Commercial Officer, MyMeds&Me said:
“The DIA Conference in Washington will be a great opportunity for industry leaders to take an in-depth look at some of the evolving principles such as the new ICH E19 guidelines and we look forward to being part of the discussion about optimizing safety data collection in late-stage pre-marketing, post-marketing studies and beyond.”
MyMeds&Me will be at stand 34 for the duration of the DIA Pharmacovigilance and Risk Management Strategies conference.
